🇺🇸 FDA
Patent

US 10967051

Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof

granted A61KA61K38/26A61K38/28

Quick answer

US patent 10967051 (Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof) held by Oramed Ltd. expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oramed Ltd.
Grant date
Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/26, A61K38/28, A61K38/55, A61K38/56